Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -11.50p -7.80% 136.00p 135.00p 137.00p 147.50p 136.00p 147.50p 111,450 16:25:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.0 -0.3 - 69.85

Verona Pharma Share Discussion Threads

Showing 12651 to 12673 of 12675 messages
Chat Pages: 507  506  505  504  503  502  501  500  499  498  497  496  Older
DateSubjectAuthorDiscuss
08/9/2017
09:27
Yes this is still grosly under priced but still needs that license with a major pharma to rocket. The market for the product is massive...
haff1
08/9/2017
08:43
Now regained my original target of 150 where I had previously sold half my EIS holding. It will be interesting to see if it breaks through the 200 & 300 resistance levels and if it ever regains the 600 level at which I would be a seller.
127tolmers
07/9/2017
23:57
At a closing price of $16.60 on Nasdaq and an exchange rate of $1.31, the Nasdaq price is equivalent to approximately £1.58 per share in the UK (based on 8 ordinary shares per ADS).
lord buffett
07/9/2017
20:02
Up over 40% on Nasdaq
bewise2
07/9/2017
09:01
Good to see some positive movement again. Trial results look very encouraging.
bonzo
07/9/2017
07:56
Presentation slides for today's webcast now available: http://investors.veronapharma.com/static-files/b1220642-7ce6-4b02-9fb2-2358f01d82e5
timbo003
07/9/2017
07:47
>>bewise Indeed I think VRP have previously demonstrated an additive effect with a SAMA, but now they have demonstrated an additive effect with a LAMA (twice a day dosing). A nice clean result and it adds further support for the 6mg dose (rather than a lower dose)
timbo003
07/9/2017
07:31
Rns: excellant news today :)
bewise2
05/9/2017
23:47
PHOWDO on what assumption do you base that . Have you had experience of Stifel as a broker and Nomad before and can you divulge further evidence to your remark. I have no knowledge of them. Cheers
shakin not stirred
05/9/2017
09:45
AS per usual
insideryou
05/9/2017
09:01
Stifel as broker and nomad = shareholders get stiffed.
phowdo
05/9/2017
08:40
Whoops whats this all about?
haff1
30/8/2017
10:29
50 000 @£1.24 Trade code 'OK' = ordinary trade with delayed publication requested. MMs have dropped the bid but that could be a buy? Any thoughts?
shearluc
21/8/2017
13:47
Verona Pharma 21 Aug 2017 10:41:48 Verona Pharma plc LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 17, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 8,130 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 122.5 pence per Ordinary Share.  Following the acquisition, Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary Shares, representing 0.12% of the Company's issued share capital.
bewise2
17/8/2017
20:53
hTTp://www.veronapharma.com/uploads/downloads/vrp-investor-presentation-august-2017-1502711536.pdf
bewise2
09/8/2017
18:26
Tip Update: Buy at 119p @ 9 Aug 2017 Tip style SPECULATIVE Risk rating HIGH Timescale LONG TERM Our previous tip We said BUY at 175p (adjusted for 50:1 share consolidation) on 22 Sep 2016 Tip performance to date -32% By Megan Boxall Verona Pharma’s (VRP) busy six months of drug development has come at a cost to the bottom line. A spike in research and development expenditure in the six months to June 2017 widened operating losses from £1.9m to £10.9m. But an increase in shares in issue meant losses per share were softer at 7.3p, compared with 8.7p in 2016. As biotechnology companies go, there is a lot to like about Verona. Its novel respiratory drug, RPL554, is undergoing several different clinical trials including two studies in Europe: one to assess appropriate dosing and one in combination with another regularly used respiratory drug. There is also an early-stage study in the US. Meanwhile, the net cash balance is healthy at £95m thanks to the group’s recent Nasdaq IPO. IC View Verona is making steady progress in an exciting part of the respiratory market and given its healthy pile of cash, we see no reason – aside from the risk of further fundraising, which looks remote – to change our buy call, at 119p. Buy. Last IC View: Buy, 133p, 2 May 2017
gersemi
05/8/2017
13:16
Summary hTTp://www.veronapharma.com/uploads/downloads/vrp-jefferies-020617-002-14969380111-1498615667.pdf
bewise2
26/7/2017
16:26
...and no effect on share price ..
haff1
26/7/2017
08:36
RNS hTTp://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/VRP/13307334.html
bewise2
25/7/2017
15:18
..this has been jam tomorrow for so so long and constantly wilting in share price Hopefully it will one day show some lasting upward trend?
haff1
23/7/2017
09:51
Just noticed this from a RNS back in April....hopefully things will be on the up in 2018....... hTTps://www.investegate.co.uk/arix-bioscience-plc/rns/group-business-verona-receives-ind-for-rpl554/201704181200046007C/ Joe Anderson, Chief Executive Officer of Arix Bioscience Plc, commented:"Verona is a dynamic company with an important drug asset, which we believe has the potential to address significant unmet needs in respiratory medicine.  RPL554 has shown potential in COPD and cystic fibrosis. This authorisation by the FDA puts it on a path towards advancing this promising candidate towards approval."  
bewise2
13/7/2017
11:45
HTTP://investors.veronapharma.com/static-files/794b4b7f-0ce7-4203-81c0-c93ec4c2860c
bewise2
27/6/2017
08:30
Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today regulatory approval in five European countries, comprising the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic, for a Phase 2b dose-ranging trial of RPL554 for maintenance treatment of chronic obstructive pulmonary disease (COPD). The trial is expected to commence in the third quarter of 2017, with top-line data expected in the second half of 2018.
bewise2
Chat Pages: 507  506  505  504  503  502  501  500  499  498  497  496  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170919 19:00:53